FDA Is Expected to Lift Restriction on Peptides, Heeding RFK Jr.'s Wishes The New York Times FDA takes first step in possible reversal of ban on some peptides The Washington Post The FDA has issued warning letters to multiple companies marketing compounded Retatrutide, an investigational drug from Eli Lilly still in Phase II trials. While early studies have shown promising weight loss results, Retatrutide BPC 157 Capsules Vios Compounding FDA Peptide Update: Category 2 Removals Explained Compounded "semaglutide" is not FDA approved semaglutide.com